Direkt zum Inhalt
Merck
  • Design and synthesis of new nonsteroidal glucocorticoid modulators through application of an "agreement docking" method.

Design and synthesis of new nonsteroidal glucocorticoid modulators through application of an "agreement docking" method.

Journal of medicinal chemistry (2005-07-08)
Mike Barker, Margaret Clackers, Derek A Demaine, Davina Humphreys, Michael J Johnston, Haydn T Jones, Francois Pacquet, John M Pritchard, Mark Salter, Stephen E Shanahan, Philip A Skone, Victoria M Vinader, Iain Uings, Iain M McLay, Simon J F Macdonald
ZUSAMMENFASSUNG

Structurally related glucocorticoid receptor (GR) binders were docked into the GR active site to select the binding mode closest to the true docking mode. This process, termed an "agreement docking method", led to the design of tetrahydronaphthalene 9. The method was validated by the syntheses of 9 and related analogues, which are potent binders of GR. 15a is a partial agonist while 9e and 15a are micromolar antagonists in a mouse mammary tumor virus transactivation assay.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Supelco
Dexamethason, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.